Health & Biotech
Check Up: As Omicron rages, rapid antigen testing specialist Atomo surges nearly 50pc
Health & Biotech
ASX Health Stocks: Cynata signs deal with FujiFilm, set to produce MSC stem cells on a mass scale
Health & Biotech
Stock Insiders: How Echo IQ is using AI and big data to better scan the heart and save lives
Health & Biotech
ASX Health Stocks: OncoSil and Neuroscientific Biopharma release positive clinical results
Health & Biotech
Exopharm secures US patent for exosomes purification technology
Health & Biotech
That was quick: Dimerix just got greenlit for Phase 3 Aussie trial in its frontline fight vs COVID-19
Health & Biotech
Check Up: Anteotech riding high with $1.9m refund, and Avecho inks supply agreement for CBD arthritis treatment
Health & Biotech
Dimerix wins more government funding to commercialise its COVID-19 therapy
Health & Biotech
ASX Health Stocks: Lumos is ready to seek regulatory approval for its COVID-19 rapid antigen test
Health & Biotech
Oh, it’s a buy: analyst upgrade places CardieX at triple current share price
Health & Biotech
Healthcare has been a hot sector. Here are the top ASX biotech stocks in 2021
Health & Biotech
‘Proven they can deliver’: EZZ ready to be life sciences leader
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.